Foundation Fader Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2007
NCT01380301
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (3)

antimony (1 trial)

imiquimod (aldara) (1 trial)

miltefosine (impavido) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leishmaniasis (Phase 2)

Leishmaniasis, Cutaneous (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3